MX375276B - Biomarcadores para canceres que responden a moduladores de la actividad de hec1. - Google Patents

Biomarcadores para canceres que responden a moduladores de la actividad de hec1.

Info

Publication number
MX375276B
MX375276B MX2014006088A MX2014006088A MX375276B MX 375276 B MX375276 B MX 375276B MX 2014006088 A MX2014006088 A MX 2014006088A MX 2014006088 A MX2014006088 A MX 2014006088A MX 375276 B MX375276 B MX 375276B
Authority
MX
Mexico
Prior art keywords
hec1
biomarkers
modulators
cancers
respond
Prior art date
Application number
MX2014006088A
Other languages
English (en)
Other versions
MX2014006088A (es
Inventor
Johnson Lau
Yu-Ling Huang
Original Assignee
Taivex Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taivex Therapeutics Corp filed Critical Taivex Therapeutics Corp
Publication of MX2014006088A publication Critical patent/MX2014006088A/es
Publication of MX375276B publication Critical patent/MX375276B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Las composiciones y métodos contemplados son diseñados para los biomarcadores y métodos relacionados con el tratamiento de la enfermedad neoplásica con el inhibidor de Hec1. El estado genético y/o los niveles de expresión de Hec1(HEC), Rb(RB1), y/o p53 (TP53) pueden ser útiles como biomarcadores para verificar la sensibilidad al tratamiento con un inhibidor de Hec1. Además, los inhibidores de Hec1 pueden mostrar efectos sinergísticos cuando se utilizan en conjunción con los fármacos citotóxicos.
MX2014006088A 2011-11-21 2012-11-19 Biomarcadores para canceres que responden a moduladores de la actividad de hec1. MX375276B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161562177P 2011-11-21 2011-11-21
PCT/US2012/065923 WO2013078145A1 (en) 2011-11-21 2012-11-19 Biomarkers for cancers responsive to modulators of hec1 activity

Publications (2)

Publication Number Publication Date
MX2014006088A MX2014006088A (es) 2015-04-08
MX375276B true MX375276B (es) 2025-03-06

Family

ID=48470233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006088A MX375276B (es) 2011-11-21 2012-11-19 Biomarcadores para canceres que responden a moduladores de la actividad de hec1.

Country Status (9)

Country Link
US (1) US9976183B2 (es)
EP (1) EP2783217B1 (es)
JP (1) JP6099662B2 (es)
CN (1) CN104395752B (es)
ES (1) ES2736999T3 (es)
MX (1) MX375276B (es)
SG (2) SG11201402143YA (es)
TW (3) TWI681054B (es)
WO (1) WO2013078145A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557465T3 (es) 2010-03-17 2016-01-26 Taivex Therapeutics Inc. Moduladores de la actividad de HEC 1 y procedimientos para ello
US11071736B2 (en) * 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Ｈｅｃ１活性調控因子及其調節方法
GB201820975D0 (en) * 2018-12-21 2019-02-06 Fund Calouste Gulbenkian Methods of cancer treatment
CN117942399A (zh) * 2022-10-31 2024-04-30 四川大学 USP5抑制剂在制备治疗p53野生型癌症的药物中的用途
CN117942400A (zh) * 2022-10-31 2024-04-30 四川大学 Beclin 1抑制剂在制备治疗p53野生型癌症的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105891A2 (en) * 2002-06-12 2003-12-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
AU2003299378A1 (en) * 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
CN102747141A (zh) * 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
WO2007004038A1 (en) * 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
KR100861278B1 (ko) * 2008-02-19 2008-10-01 고려대학교 산학협력단 암 치료용 리보핵산 의약 조성물
CN102088973A (zh) 2008-05-15 2011-06-08 杜克大学 与热休克转录因子激活化合物及其靶标有关的组合物和方法
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP2309273B1 (en) * 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
ES2557465T3 (es) 2010-03-17 2016-01-26 Taivex Therapeutics Inc. Moduladores de la actividad de HEC 1 y procedimientos para ello

Also Published As

Publication number Publication date
EP2783217A1 (en) 2014-10-01
ES2736999T3 (es) 2020-01-09
TW201331371A (zh) 2013-08-01
SG11201402143YA (en) 2014-06-27
WO2013078145A1 (en) 2013-05-30
TW201706416A (zh) 2017-02-16
US20130171634A1 (en) 2013-07-04
SG10201506881PA (en) 2015-10-29
TWI681055B (zh) 2020-01-01
MX2014006088A (es) 2015-04-08
EP2783217A4 (en) 2015-05-27
EP2783217B1 (en) 2019-04-24
JP6099662B2 (ja) 2017-03-22
US9976183B2 (en) 2018-05-22
TWI641386B (zh) 2018-11-21
TW201705987A (zh) 2017-02-16
HK1202922A1 (en) 2015-10-09
JP2015500008A (ja) 2015-01-05
TWI681054B (zh) 2020-01-01
CN104395752B (zh) 2017-09-15
CN104395752A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2015002409A (es) Métodos y composiciones para el tratamiento de una afección genética.
MX2021009673A (es) Moduladores de ror-gamma.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
MX338015B (es) Composiciones que comprenden un componente de estabilidad de la vida util.
UY33886A (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
UY36075A (es) Derivados de tubulisina
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
MX383590B (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
CR20150326A (es) Inhibidores de autotaxina
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
MX2016006815A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
PE20151023A1 (es) Triazolopirazinas
MX2015008241A (es) Metodos para el tratamiento de espasmos gastrointestinales.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2014006088A (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2

Legal Events

Date Code Title Description
FG Grant or registration